New study monitors infection risks in cutting-edge blood cancer treatment

NCT ID NCT07609576

First seen May 29, 2026 · Last updated Jun 13, 2026 · Updated 3 times

Summary

This study follows 350 adults with blood cancers like lymphoma or multiple myeloma who are being treated with bispecific antibodies. The goal is to track how often infections occur, what types, and how serious they are. Researchers also want to find out what makes some patients more likely to get infections and how infections affect treatment results.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Infanta Leonor University Hospital

    RECRUITING

    Madrid, Madrid, 28041, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital Infanta Leonor

    RECRUITING

    Madrid, Madrid, 28005, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.